Optometry guidance tells clinicians how to counsel GLP-1 patients on NAION

A clinical briefing published in September 2026 walks optometrists through the evolving evidence on GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy, or NAION, and tells them how to counsel patients rather than debate whether the signal is real.^[1] The guidance points to a retrospective study of 710 patients with type 2 diabetes in which 17 of 194 semaglutide users, or 8.9%, developed NAION compared with six of 516 matched controls, or 1.8%, a hazard ratio of 4.3.^[1] Among 979 patients treated for obesity in the same study, 20 of 361 semaglutide users developed NAION versus three of 618 controls, a hazard ratio of 7.6.^[1]

NAION causes sudden, usually painless vision loss in one eye, typically noticed on waking, and has no proven treatment; the second eye is affected in up to 30% of cases over time.^[1] It is already the most common acute optic nerve condition in adults over 50, occurring in roughly 2 to 10 people per 100,000 each year, and shares risk factors with the conditions GLP-1 drugs are prescribed for, including diabetes, high blood pressure, and sleep apnea.^[1] That overlap makes it hard to know how much of any added risk comes from the drug itself.

Since the original 2024 study, more than a dozen studies have produced mixed results. Some registry studies from Denmark and Norway found roughly double the risk in semaglutide users, while a US analysis of three insurance databases found a hazard ratio of 1.85.^[1] Other large studies, including one covering nearly 300,000 patients and another covering more than 2.4 million people with type 2 diabetes, found no significant increase in NAION risk tied to semaglutide.^[1] A separate analysis of nearly 1.6 million patients across five studies, published in the journal Neurology, found semaglutide users had a 152% higher risk of NAION overall and a 141% higher risk among those with diabetes, though the actual rate worked out to about 118 cases per 100,000 semaglutide users overall and 125 per 100,000 among those with diabetes.^[2] Meta-analyses of randomized trials have been inconsistent, with one finding a signal for NAION and another, looking at the broader drug class, finding no statistically significant increase.^[1]

Why it matters for patients

The new guidance does not tell doctors or patients to stop these medications. Both the briefing and outside eye specialists say the well-documented cardiovascular and metabolic benefits of GLP-1 drugs are expected to outweigh the absolute risk of NAION even if the link turns out to be real.^[1][2] Instead, the guidance asks optometrists to check for a